| Similar Articles |
|---|
 |
Chemistry World
October 28, 2014
Phillip Broadwith |
Amgen stacks up additional job cuts US biotech heavyweight Amgen is to cut an extra 600 -- 1100 jobs by the end of 2015, on top of the 2900 the company earmarked for the chop in August.   |
Chemistry World
August 1, 2014
Sarah Houlton |
Amgen to shed 2400-2900 jobs Most of the job losses will be in the US, predominantly at the former Immunex research facility in Seattle and two biologics manufacturing sites in Colorado. |
Chemistry World
January 20, 2012
Sarah Houlton |
Takeda slashes 10% of its workforce This represents about 10% of its workforce, and the cuts will be made in research, commercial and admin sections of the business. |
The Motley Fool
February 22, 2005
Rich Duprey |
Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%. |
Chemistry World
May 20, 2011
Sarah Houlton |
Takeda expands into Europe with Nycomed deal Japanese pharma company Takeda is to acquire Swiss-headquartered rival Nycomed for 9.6 billion. If the antitrust authorities give the go-ahead, the takeover should be completed by late summer. |
Bio-IT World
May 19, 2004
Barbara Depompa |
Turning Sugar into Science The landmark building that housed the New England Confectionery Company in Revere, Mass. is being transformed into the new headquarters for the Novartis Institutes for BioMedical Research. |
Chemistry World
May 30, 2012 |
Takeda buys into Brazil for 540m reals Brazilian company Multilab made sales of BRL140 million in 2011, primarily from generics and over-the-counter branded products, including its leading cold and flu brand Multigrip. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
Inc.
July 2005
Larry Olmsted |
Nonstop Innovation How Cambridge Consultants transforms its employees into entrepreneurs. |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city. |
The Motley Fool
August 21, 2009
Brian Orelli |
Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend. |
Chemistry World
November 7, 2012
Andrew Turley |
Takeda buys Envoy for $140m The move gives Takeda access to Envoy's 'BacTrap' technology for labeling and extracting the protein-making components of specific types of cells. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
Pharmaceutical Executive
September 1, 2008
Walter Armstrong |
The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08. |
Pharmaceutical Executive
June 1, 2005
Seth Berkley |
Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer. |
Pharmaceutical Executive
June 1, 2013 |
When Gurus Get It Wrong Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell. |
The Motley Fool
April 29, 2010
Brian Orelli |
Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business. |
The Motley Fool
September 7, 2005
Rich Duprey |
Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
The Motley Fool
December 13, 2007
Brian Orelli |
Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections. |
The Motley Fool
March 30, 2011
Brian Orelli |
Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Productivity, Reputation are Keys to Global Leadership As CEO of Japan's largest pharmaceutical company and chair of Keizai Doyukai representing Japan's corporate business community, Yasuchika Hasegawa has the platform to pursue a two-pronged agenda that artfully fuses global and domestic priorities. |
Chemistry World
July 24, 2009
Matt Wilkinson |
Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared. |
Pharmaceutical Executive
April 10, 2014
Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated? |
The Motley Fool
October 6, 2004
Rich Duprey |
Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices. |
The Motley Fool
September 2, 2010
Luke Timmerman |
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical. |
Fast Company
Neal Ungerleider |
Why Boston's City Hall Wants A Chief Digital Officer Mayor Marty Walsh announced last Wednesday that the city, which anchors America's third-largest startup hub, is launching a huge initiative for local high-tech firms. |
The Motley Fool
June 26, 2008
Brian Lawler |
Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs. |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
InternetNews
July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain. |
Chemistry World
October 11, 2007
Hepeng Jia |
China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest. |
Chemistry World
May 11, 2015
Phillip Broadwith |
Takeda offers $2.4bn to settle diabetes litigation Japanese drug company Takeda has put aside $2.7 billion to cover settlements of US product liability court cases relating to its diabetes drug Actos (pioglitazone). |
Chemistry World
January 22, 2014
Mico Tatalovic |
Croatia's vaccines manufacturer left hanging as it enters administration The government has pledged to find a solution and to keep production of key products in Croatia as it looks for strategic partners to invest in restructuring the ailing institute. |
Scientific American
April 10, 2006
Christine Soares |
Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
The Motley Fool
September 16, 2009
Brian Orelli |
Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration. |
Chemistry World
September 11, 2014
Emma Stoye |
Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters. |
The Motley Fool
July 5, 2006
Rich Duprey |
Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle. |
Chemistry World
March 17, 2011
Hepeng Jia |
International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation. |
Chemistry World
December 17, 2015
Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
